Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014 · New England Journal of Medicine · 1,825 citations
https://doi.org/10.1056/nejmoa1406037
A
Axel Hauschild
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
815
Papers
72.5K
Citations
110
h-index
410
i10-index
Axel Hauschild is an academic researcher from Christian-Albrechts-Universität zu Kiel. The author has contributed to research in topics: Cutaneous Melanoma Detection and Management & Melanoma and MAPK Pathways & CAR-T cell therapy research. The author has an h-index of 110, co-authored 693 publications.
ORCID: 0000-0002-1212-9587Papers by this author
worksAdjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
2017 · New England Journal of Medicine · 1,459 citations
https://doi.org/10.1056/nejmoa1708539
Melanoma
2018 · The Lancet · 1,435 citations
https://doi.org/10.1016/s0140-6736(18)31559-9
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 · New England Journal of Medicine · 1,419 citations
https://doi.org/10.1056/nejmoa1113713
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
2019 · New England Journal of Medicine · 1,316 citations
https://doi.org/10.1056/nejmoa1904059
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
2017 · BMC Cancer · 407 citations
https://doi.org/10.1186/s12885-017-3286-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat